Drug Delivery Systems Excellence Center and Department of Pharmaceutical Technology, Faculty of Pharmaceutical Sciences, Prince of Songkla University, Hat Yai, 90112, Songkhla, Thailand.
Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmaceutical Sciences, Nnamdi Azikiwe University, Agulu, Anambra State, Nigeria.
AAPS PharmSciTech. 2024 Jul 9;25(6):156. doi: 10.1208/s12249-024-02879-7.
Commercial topical formulations containing itraconazole (poorly water soluble), for mycotic infections, have poor penetration to infection sites beneath the nails and skin thereby necessitating oral administration. To improve penetration, colloidal solutions of itraconazole (G1-G4) containing Poloxamer 188, tween 80, ethanol, and propylene glycol were prepared and incorporated into HFA-134-containing sprays. Formulations were characterized using particle size, drug content, and Fourier-transform infrared spectroscopy (FTIR). In vitro permeation studies were performed using Franz diffusion cells for 8 h. Antimycotic activity on Candida albicans and Trichophyton rubrum was performed using broth micro-dilution and flow cytometry, while cytotoxicity was tested on HaCaT cell lines. Particle size ranged from 39.35-116.80 nm. FTIR and drug content revealed that G1 was the most stable formulation (optimized formulation). In vitro release over 2 h was 45% for G1 and 34% for the cream. There was a twofold increase in skin permeation, fivefold intradermal retention, and a sevenfold increase in nail penetration of G1 over the cream. Minimum fungicidal concentrations (MFC) against C. albicans were 0.156 and 0.313 µg/mL for G1 and cream, respectively. The formulations showed optimum killing kinetics after 48 h. MFC values against T. rubrum were 0.312 and 0.625 µg/mL for the G1 and cream, respectively. Transmission electron microscopy revealed organelle destruction and cell leakage for G1 in both organisms and penetration of keratin layers to destroy T. rubrum. Cytotoxicity evaluation of G1 showed relative safety for skin cells. The G1 formulation showed superior skin permeation, nail penetration, and fungicidal activity compared with the cream formulation.
含有酮康唑(水溶性差)的商业局部制剂,用于治疗真菌感染,但对指甲和皮肤下的感染部位的穿透力差,因此需要口服。为了提高穿透力,制备了含有泊洛沙姆 188、吐温 80、乙醇和丙二醇的酮康唑(G1-G4)胶体溶液,并将其纳入 HFA-134 喷雾中。使用粒径、药物含量和傅里叶变换红外光谱(FTIR)对制剂进行了表征。使用 Franz 扩散细胞进行了 8 小时的体外渗透研究。使用肉汤微量稀释法和流式细胞术对白色念珠菌和红色毛癣菌进行了抗真菌活性测试,同时在 HaCaT 细胞系上测试了细胞毒性。粒径范围为 39.35-116.80nm。FTIR 和药物含量表明 G1 是最稳定的制剂(优化制剂)。在 2 小时内的体外释放量,G1 为 45%,乳膏为 34%。G1 在皮肤中的渗透增加了两倍,在真皮中的保留增加了五倍,在指甲中的渗透增加了七倍。G1 对白色念珠菌的最小抑菌浓度(MFC)分别为 0.156 和 0.313μg/ml,而乳膏的 MFC 值分别为 0.312 和 0.625μg/ml。两种制剂在 48 小时后表现出最佳的杀菌动力学。G1 对红色毛癣菌的 MFC 值分别为 0.312 和 0.625μg/ml,而乳膏的 MFC 值分别为 0.312 和 0.625μg/ml。透射电子显微镜显示 G1 在两种生物体中均破坏细胞器并导致细胞渗漏,穿透角蛋白层以破坏红色毛癣菌。G1 的细胞毒性评估显示对皮肤细胞相对安全。与乳膏制剂相比,G1 制剂具有更好的皮肤渗透、指甲渗透和杀菌活性。